JNJ

$237.79

Public overview and default valuation.

Log in to track this stock.

Valuation Details
Default assumptions: 10Y forecast, 9% market return, 2.5% terminal growth, 2.56% trendline growth.
Want to create your own valuation? Create a free account.
$375.89

With 20% Margin of Safety (MoS):

$300.71
26.46% upside
Capital Efficiency
Average Quarterly ROIC
7.43%
Cost of Capital (estimated)9%
Value StatusUnderperforming Capital

The company is earning below its required return. This may indicate inefficient use of capital or excess cash that isn't being reinvested.

Complete historical ROIC is available with
.
Fundamental Score
57
NeutralWeighted across 6 signals
DCF Discount
26.5% discount to price
94
FCF Yield
5.1% trailing FCF yield
78
ROIC vs WACC
ROIC 7.4% vs WACC 9.0% (0.8x)
41
Net Debt / FCF
0.9x net debt to FCF
81
Buybacks
Share count growing
30
FCF CAGR (5Y)
1.7% 5Y FCF CAGR
25
Strengths: DCF Discount, FCF Yield. Concerns: Buybacks, FCF CAGR (5Y).
Narrative Score
81
Strong
Weighted across 6 recent drivers · Last 30 daysVs 6-Month Baseline: High (91th pct)
Trend: Improving upConfidence: 100%Updated: 5h ago
Sources: 220 (News 200 · Analyst 20)
Drivers
74 regulatory scrutiny+5.5
114 news sentiment+3.2
Analyst upgrades+0.1
Downgrade headlines+0.1
Upgrade headlines+0.1
Restructuring-0.1
Other Metrics
P/E21.6
Profit Margin28.5%
Owner Earnings$37.44b
One Dollar Premise46.00%
Debt/Equity1.47
Current Ratio1.11
PEG-1.571
Free Cash Flow (in millions)
20052006200720082009201020112012201320142015201620172018201920212022202320232024
$14,509$16,986$18,559$18,038$18,936$18,769$17,191$18,330$21,009$22,185$22,742$21,993$24,335$25,871$26,914$26,883$27,062$27,334$25,203$29,344
How Intrinziq Estimates Fair Value

Intrinziq estimates Johnson & Johnson's intrinsic value using a discounted cash flow (DCF) model based on free cash flow trends and a market-based discount rate. The model projects future cash flows over ten years and discounts them using a market return assumption to estimate fair value.

Johnson & JohnsonHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Last updated: Feb 06, 2026
Data sources: Financial Modeling Prep
This valuation is based on assumptions and publicly available data. It is not financial advice or a recommendation to buy or sell any security. Always do your own research before making investment decisions.